Ask about this productRelated genes to: FKBPL antibody
- Gene:
- FKBPL NIH gene
- Name:
- FKBP prolyl isomerase like
- Previous symbol:
- -
- Synonyms:
- DIR1, NG7, WISp39
- Chromosome:
- 6p21.32
- Locus Type:
- gene with protein product
- Date approved:
- 2001-04-06
- Date modifiied:
- 2018-11-01
Related products to: FKBPL antibody
Related articles to: FKBPL antibody
- Respiratory tract infections (RTIs) remain a major global cause of morbidity, yet the causal role of circulating plasma proteins in RTI susceptibility is unclear. We aimed to systematically identify plasma proteins that causally influence the risk of upper and lower respiratory tract infections (URTIs, LRTIs) using a proteome-wide Mendelian randomization (MR) framework. - Source: PubMed
Publication date: 2026/02/11
Yuan YuhuaLiu BinChen ShuhuiWang ManliZhao ShuyueMao Yingying - Impaired angiogenesis underpins cardiovascular disease, particularly in people with diabetes; however, molecular mechanisms are still poorly understood. This study aims to decipher the role of an emerging antiangiogenic protein, FKBPL (FK506-binding protein-like), on cardiac structure and function, vascular integrity, and inflammatory signaling in in vivo and in vitro models of diabetes. - Source: PubMed
Publication date: 2026/02/12
Alqudah AbdelrahimEdgar Kevin SO'Neill Karla MMcNally RossZhand SarehLe NatalieChhor MichaelShort AmyKavurma Mary MLopez-Campos Guillermo HRobson TracyGrieve David JMcClements Lana - Lung squamous cell carcinoma (LUSC) is the second most prevalent type of lung cancer worldwide. Despite its global health burden, the molecular mechanisms driving LUSC remain poorly characterized, posing considerable challenges for the development of targeted preventive therapies. Here, by integrating human plasma proteomes ( = 54,219) with GWAS summary data for LUSC (7426 cases and 55,627 controls), we performed genome-wide Mendelian randomization (MR) and colocalization analyses to identify potential druggable targets associated with LUSC risk. After applying Bonferroni correction, sensitivity analyses, and reverse causation detection, we identified 12 potential druggable proteins significantly associated with LUSC risk. Five of these proteins (DOK2, FKBPL, NCF2, PDIA3, and TCL1A) showed strong evidence of colocalization. Furthermore, protein-protein interaction (PPI) networks and druggability assessments were used to refine therapeutic target selection. Additionally, mediation analyses were performed to elucidate the mediating effects of modifiable risk factors on the relationship between plasma proteins and LUSC risk, and we identified 14 modifiable risk factors that could mitigate LUSC risk through targeted interventions. More importantly, we stratified the 12 proteins into four tiers based on colocalization, differential expression, PPI networks, and druggability potential. Notably, DOK2 emerged as a Tier 1 target, while FKBPL, NCF2, AXL, and PDIA3 were classified as Tier 2 targets, representing promising candidates for further drug development. Overall, we identified 12 proteins with druggable potential associated with LUSC risk and demonstrated how modifiable risk factors mediate these associations. These findings advance our understanding of LUSC etiology and provide a foundation for developing targeted therapeutic strategies while emphasizing the importance of addressing modifiable risk factors in both prevention and treatment efforts. - Source: PubMed
Publication date: 2025/11/21
Zhang YutongZhao YiranFan LingliLi XiaoyanLi Yuanyuan - Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by a complex interplay of molecular factors. Despite advances in understanding its pathophysiology, diagnostic delays and the absence of personalized treatment strategies remain significant challenges. This review provides a comprehensive analysis of imaging techniques and molecular approaches to improve disease characterization. Advanced imaging methods, including magnetic resonance imaging, positron emission tomography, and artificial intelligence (AI)-driven models, have enhanced diagnostic accuracy, reduced variability in interpretation, and facilitated early disease detection. In parallel, omics technologies have provided valuable insights into disease pathogenesis. Genomic studies have identified susceptibility loci beyond human leukocyte antigen B27, implicating key immune pathways such as interleukin-23/interleukin-17 signaling. Epigenomic modifications, particularly DNA methylation, play a key role in regulating gene expression in immune cells, especially within genetically predisposed loci. Transcriptomic studies have uncovered dysregulated immune pathways and revealed novel cellular players in disease pathogenesis, including CD99 neutrophils, natural killer cells, and microRNAs-important post-transcriptional regulators that have shown high diagnostic accuracy when assessed in peripheral blood mononuclear cells. Proteomic analyses have further contributed by identifying potential biomarkers and therapeutic targets in blood using advanced technologies, highlighting molecules such as tumor necrosis factor, FK506-binding protein-like (FKBPL), mitogen-activated protein kinase 14 (MAPK14), interleukin 7 receptor, and interleukin-23 receptor, among others. Future research should focus on combining multi-omics data with AI-driven approaches to improve biomarker discovery, optimize patient classification, and guide personalized treatments. Bridging the gap between molecular insights and clinical applications will enable precision medicine strategies, improving early diagnosis and therapeutic outcomes in axSpA. - Source: PubMed
Publication date: 2025/12/17
Arias-de la Rosa IvánMartín-Salazar Jesús EduardoCuesta-López LauraLópez-Medina C ClementinaEscudero-Contreras AlejandroCollantes-Estévez EduardoBarbarroja NuriaPuche-Larrubia María Ángeles - Preeclampsia is a multifactorial pregnancy disorder characterized by the new onset of hypertension and organ damage. Mitochondrial dysfunction is central to preeclampsia pathogenesis leading to placental dysfunction and oxidative stress. This study aims to elucidate the mechanisms of mitochondrial dysfunction in first-trimester trophoblast cells and to assess the therapeutic potential of aspirin, metformin, resveratrol, and a FKBPL-based peptide (AD-01) as a strategy to improve trophoblast mitochondrial health. A 2D in vitro model using the first trimester ACH-3Ps trophoblasts were developed to mimic preeclampsia-like conditions, including hypoxia-inducible factor (HIF)-1α activation (DMOG, 100 μM), mitochondrial dysfunction (Rho-6G, 1 μg/mL), or inflammation (TNF-α, 10 ng/ml). Cells were treated for 48 h with metformin (0.5 mM), resveratrol (15 μM), AD-01 (100 nM), or aspirin (0.5 mM), in the presence of DMOG, Rho-6G or TNF--α. Mitochondrial dynamics were assessed by immunofluorescence staining, the Seahorse XF Mito Stress Test, and RT-qPCR for key genes expression regulating mitochondrial fusion (mfn1), fission (dnm1l), and autophagy (atg5, map1lc3b). Preeclampsia-mimicking stimuli significantly altered mitochondrial networks by reducing mitochondrial size (p <0.05-0.0001), increasing circularity (p < 0.05-0.0001), and decreasing mitochondrial number per cell (p < 0.0001). Metformin notably restored mitochondrial architecture under inflammatory stress, normalized mfn1 (p < 0.05) and atg5 expression (p < 0.001), and improved cellular bioenergetics. Aspirin improved mitochondrial morphology under hypoxic conditions and reduced oxygen consumption (p < 0.01). Resveratrol and AD-01 showed context-dependent protective effects, including reduced basal respiration under inflammatory stress (p < 0.0001). These findings demonstrate that hypoxia, inflammation, and mitochondrial dysfunction contribute to mitochondrial pathology in preeclampsia and highlight aspirin, metformin, resveratrol, and AD-01 as promising targeted therapies. Tailored interventions may improve mitochondrial health and pregnancy outcomes in women with preeclampsia. - Source: PubMed
Publication date: 2025/12/15
Afrose DinaraAlfonso-Sánchez SofíaPhilp AshleighHansbro Philip MSu Qian PeterMcClements Lana